The CSHQ-PT total score mean was 47.0 ± 7.2 (95% CI: 46.10-47.81). Comparing the mean total scores from three age subgroups (2 to 4, 5 to 7, and 8 to 10 years), we found a trend for a gradual decrease: 49.4 ± 7.8, 46.2 ± 6.1, 45.11 ± 7.1, respectively (p < 0.001). There were no differences between boys and girls. Children MK-1775 cost identified by the parents as “Problem sleepers” had a higher mean score then “Non-problem sleepers”: 54.5 versus 45.9, respectively (p < 0.001). The internal consistency of the CSHQ-PT was 0.78 for the full

33-item scale (95% CI 0.746 – 0.809) and ranged from 0.44 to 0.74 for the subscales (Table 2). Eliminating items 21, 26, 28, 32 and 33 would increase the total scale α to 0.81 but would decrease the subscales α, except for item 21. Eliminating items

7 and 21 would increase Sleep Anxiety α from 0.44 to 0.57. The answers for children aged 2 to 3 years old (n = 68) showed internal consistencies that FRAX597 clinical trial were similar to the older ones: total scale 0.78, Bedtime Resistance 0.74, Sleep Duration 0.72, Sleep Anxiety 0.53, Night Wakings 0.58, Parasomnias 0.57, Sleep-Disordered Breathing 0.74 and Daytime Sleepiness 0.64. Retest questionnaires were sent to 138 parents with a 57.2% response rate. Twenty one questionnaires presented exclusion criteria and 58 were used in test-retest reliability analysis. The total CSHQ score showed a strong correlation in retests (0.79, p < 0.001). Subscale score correlations ranged from 0.59 to 0.85 (Table 3). The sleep

schedules (bedtime and wake time in weekdays and weekends) showed very strong correlations (from 0.86 to 0.96) except for the bedtime in the weekend (0.64, p < 0.001). The child's usual amount Methamphetamine of sleep each day also showed a strong correlation in retests (r=0.79, p < 0.001). Our data did not fit the original CSHQ eight domain structure in Confirmatory Factor Analysis as CFI was 0.863 and RMSEA was 0.063. The Exploratory Factor Analysis extracted five factors: daytime somnolence (items 26, 27, 28, 29, 30 and 31), difficulty in settle to sleep alone/sleep anxiety (items 3, 4, 5, 8 and 16), night wakings and parasomnias (items 12, 13, 14, 22, 23, 24 and 25), sleep duration (items 1, 2, 6, 9, 10, 11 and 25) and Sleep-disordered breathing (items 18, 19 and 20). The CSHQ has already been used for children aged 2 to 3 years but the validation data for this age band is scarce.28 In this study, we found total scale and subscale internal consistencies that were similar to older children.12, 17 and 18 Considering the full sample, the total scale α (0.78) is above the recommended value of 0.70.24 It is also higher than the values described in community samples from the United Sates and Germany (Table 2) and identical to an US clinical sample.12 and 18 The CSHQ-PT also evidenced convergent validity with the overall parent evaluation of sleep difficulties as children identified as “Problem sleepers” got higher total scores.